Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M (REGN:NASDAQ)

Summary by Seeking Alpha
Regeneron (REGN) Q1 earnings: EPS and revenue beat, Dupixent and EYLEA sales trends, new $3B buyback, and updated 2026 guidance—read more now.

1 Articles

Seeking AlphaSeeking Alpha
Lean Right

Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M (REGN:NASDAQ)

Regeneron (REGN) Q1 earnings: EPS and revenue beat, Dupixent and EYLEA sales trends, new $3B buyback, and updated 2026 guidance—read more now.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Wednesday, April 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Tarrytown icon

Tarrytown

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal